Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer-Reference-Cited by-同舟云学术

Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer

Published:2023-10-15 Issue:20 Volume:62 Page:3001-3004
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Sumii Masahiko¹,Namba Masashi²,Tokumo Kentaro²,Yamauchi Masami²,Okamoto Wataru³,Hattori Noboru¹,Sugiyama Kazuhiko³

Affiliation:

1. Department of Respiratory Medicine, Hiroshima University Hospital, Japan

2. Department of Clinical Oncology, Hiroshima University Hospital, Japan

3. Department of Cancer Treatment Center, Hiroshima University Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/62/20/62_1110-22/_pdf

Reference17 articles.

1. 2. Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 8: 822-835, 2018.

2. 3. Arbour KC, Jordan E, Kim HR, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin Cancer Res 24: 334-340, 2018.

3. 4. Riely GJ, Jordan E, Kim HR, et al. Association of outcomes and co-occurring genomic alterations in patients with KRAS-mutant non-small cell lung cancer. J Clin Oncol 34: 9019, 2016.

4. 5. Proulx-Rocray F, Routy B, Mohamad Nassabein R, et al. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and the influence of the NLR in NSCLC patients with immunotherapy. J Clin Oncol 39: e21010, 2021.

5. 6. Di Federico A, De Giglio A, Parisi C, Gelsomino F. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: prognostic rather than predictive? Eur J Cancer 157: 108-113, 2021.